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Abstract
Purpose Tapentadol is a dual-acting mu-opioid receptor agonist and noradrenaline reuptake inhibitor with non-inferior 
analgesic efficacy to oxycodone and better gastrointestinal tolerability than full mu-opioid receptor agonists. Tapentadol is 
approved for cancer pain in Japan; however, real-world evidence on tapentadol’s effectiveness and safety for cancer-related 
pain in Japan is limited.
Methods This retrospective study evaluated the effectiveness, safety, and tolerability of tapentadol (by patient type—opioid-
naïve and opioid-tolerant) in 84 patients with moderate-to-severe cancer pain at Ichikawa General Hospital between Sep-
tember 2014 and August 2016.
Results Almost 93% of patients achieved clinically relevant pain relief within 4 days (median). Over 90% of patients with 
neuropathic pain or mixed pain and all patients with nociceptive pain were responders. Pain intensity significantly decreased 
from baseline through to the end of maintenance period in opioid-naïve and opioid-tolerant patients. No patients discontinued 
tapentadol due to serious adverse events. No opioid-naïve patients experienced nausea or vomiting during tapentadol treat-
ment. Only three opioid-tolerant patients experienced nausea which was considered to be related to tapentadol.
Conclusion Tapentadol is effective and well tolerated in opioid-naïve and opioid-tolerant patients with cancer pain of vary-
ing pathophysiology, including those with nociceptive and/or neuropathic components. Tapentadol may be considered for 
first-line use in moderate-to-severe cancer-related pain.
Keywords Tapentadol · Cancer pain · Neuropathic pain · Japan
Introduction
Pain affects up to 70% of patients with cancer, especially 
those in the advanced stages of the disease [1]. Even after 
completing anti-cancer treatment, more than 30% of patients 
suffer from pain that requires treatment [2]. Cancer pain 
often involves a “mixed” pain type arising from both noci-
ceptive and neuropathic pain [3]. The prevalence of cancer-
related neuropathic pain is variable and ranges between 20 
and 40% [4–7], whereas that for cancer-related mixed pain 
is reported to be up to 40% [4].
Neuropathic pain is defined by the International Associa-
tion for the Study of Pain as “pain that arises directly from 
a lesion or diseases affecting the somatosensory system” 
[8]. Neuropathic pain is diagnosed using sensory examina-
tions and diagnostic tests such as neuroimaging or neuro-
physiological tests to confirm a lesion or disease that may 
contribute to neuropathic pain [9]. Pharmacological options 
for cancer-related neuropathic pain include treatment with 
opioids, non-opioids, and adjuvant therapies such as tricy-
clic antidepressants or anticonvulsants [10]. Nevertheless, 
neuropathic pain remains a challenge to treat as effective 
management hinges on the reliable diagnosis, detection, and 
selection of the appropriate pharmacological agent by the 
primary physician [10, 11].
Opioids are the cornerstone in the treatment of moder-
ate-to-severe cancer-related pain [12]. Opioids, although 
effective at alleviating cancer pain, may cause adverse 
effects such as constipation, sedation, and pruritus [13]. 
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Previous exposure to opioids may also influence analgesic 
response and adverse effects. Equianalgesic doses of opi-
oids have shown to induce more adverse effects with less 
analgesia in opioid-tolerant patients compared to opioid-
naïve patients [14]. Guidelines by the European Society for 
Medical Oncology [12] and the Japanese Society of Pallia-
tive Medicine [15] recommend opioid switching or rotation 
to improve analgesic response or minimize the severity of 
adverse effects.
Tapentadol is a centrally acting mu-opioid receptor 
agonist and noradrenaline reuptake inhibitor [16]; both 
mechanisms of action contribute to its anti-nociceptive and 
anti-neuropathic pain effects [17–19]. Tapentadol has dem-
onstrated to be non-inferior to oxycodone [20] and morphine 
[21] at reducing pain intensity with better gastrointestinal 
tolerability in patients with cancer pain. Improved gastroin-
testinal tolerability with tapentadol may be attributed to its 
dual mechanism of action and weaker affinity for the mu-
opioid receptor compared to other full mu-opioid receptor 
agonists [19, 22]. Furthermore, tapentadol has been studied 
in both opioid-naïve and opioid-tolerant patients with pain as 
a direct consequence of cancer or from anti-cancer treatment 
[16]. Opioid switching to tapentadol has shown to be prac-
tical for improving pain relief and reducing the severity of 
adverse effects [23, 24]. Despite its approval for cancer pain 
in Japan in 2014, there is paucity of real-world evidence on 
the efficacy, safety, and tolerability of tapentadol in cancer 
pain management. Thus far, only one real-world study has 
studied the effectiveness and safety of tapentadol in Japanese 
patients with cancer-related pain that is unresponsive to first-
line opioid therapy [24].
The present study aimed to evaluate the effectiveness, 
safety, and tolerability of tapentadol by patient type (opioid-




We retrospectively evaluated 92 patients with cancer pain 
treated with tapentadol at Ichikawa General Hospital in 
Japan between September 2014 and August 2016. The 
study included opioid-naïve or opioid-tolerant patients who 
fulfilled the following criteria: diagnosed with moderate-
to-severe cancer pain (numerical rating scale; NRS ≥ 4); 
required opioids for cancer pain control; did not require 
adjuvant analgesics; and dissatisfied with the cancer pain 
relief from current analgesic treatment.
Opioid-naïve patients were those not receiving opioid 
analgesic on a daily basis and, therefore, have not developed 
tolerance to opioids. Opioid-tolerant patients were those 
already treated with other opioid analgesics—i.e., at least 
25 mcg/h fentanyl patch, at least 30 mg of morphine daily, 
at least 20 mg of oral oxycodone daily, or an equianalgesic 
dose of another opioid for a week or longer. Neuropathic 
pain was diagnosed based on a history of relevant neurologi-
cal lesion, clinical evaluation of pain distribution that was 
anatomically consistent with the suspected location of the 
lesion and the existence of allodynia or hypoesthesia, and 
objective diagnostic tests (such as computed tomography 
and/or magnetic resonance imaging) confirming the pres-
ence of nerve lesion [25]. The study was approved by the 
research ethics committee of Ichikawa General Hospital 
(reference I 14-45R; approved on 24th Mar 2017). Patients 
were given the opportunity to opt out.
Treatment
Opioid-naïve patients were prescribed an initial tapentadol 
dose of 25 or 50 mg twice daily (50–100 mg/day). Opioid-
tolerant patients were prescribed an initial tapentadol dose 
of 50–400 mg/day. Tapentadol doses were calculated based 
on previous opioid consumption, and at a conversion ratio of 
5:1 (tapentadol:oxycodone). Patients discontinued previous 
opioid analgesic treatment prior to receiving their first dose 
of tapentadol.
Oral immediate release oxycodone (5 or 10 mg) was 
available as rescue medication for breakthrough pain without 
limit on the number and timing of doses per day. Follow-
ing stable dosing of tapentadol for at least 3 days, tapent-
adol doses were titrated at physician’s discretion. Tapent-
adol doses could be increased in increments of either 50 or 
100 mg, up to a maximum of 400 mg/day for opioid-naïve 
patients or 600 mg/day for opioid-tolerant patients.
Study endpoints
Effectiveness
Pain intensity was assessed by physicians or nurses at the 
following time-points: baseline, initial pain relief, and main-
tenance period. Patients rated their pain intensity using the 
NRS from 0 (no pain) to 10 (worst pain imaginable). Patients 
entered the maintenance period after achieving satisfactory 
pain relief and once tapentadol titration was completed. Sat-
isfactory pain relief was defined as not having taken any 
rescue medications for breakthrough pain more than twice 
daily during a 3-day treatment period with stable doses of 
tapentadol. Following tapentadol titration, clinically relevant 
pain relief was defined as having at least 50% reduction in 
NRS score from baseline; patients who had clinically rel-
evant pain relief were considered “responders”.
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Safety and tolerability
Safety assessments included recorded nausea and vomiting 
and serious adverse events. We specifically assessed nausea 
and vomiting, because these are common adverse effects of 
opioid treatment. Data on constipation were not collected in 
this study, because prophylactic laxatives had been already 
prescribed or were prescribed at the time of tapentadol ini-
tiation in most patients. Reasons for discontinuation of tap-
entadol were also assessed.
Statistical analyses
Demographics, patient characteristics, and effectiveness and 
safety endpoints were summarized using descriptive statis-
tics. The effectiveness and safety endpoints were also evalu-
ated by patient type (i.e., opioid-naïve and opioid-tolerant). 
Pain intensity scores between time-points (baseline vs. ini-
tial pain relief; initial pain relief vs. maintenance period) 
were compared using the two-way analysis of variance test. 
Discrete variables were compared using the Friedman test 
and post hoc Bonferroni correction. Statistical analyses were 
performed using Microsoft Office Excel 2013 (Los Angeles, 




A total of 92 patients entered the study. Eight patients had 
oral intake difficulty due to general physical health deteriora-
tion and were excluded from the analysis, leaving 84 patients 
for analysis. Patient demographics and characteristics are 
summarized in Table 1. More than half (59.5%) of the study 
population were male and the mean (standard deviation, 
SD) age of patients was 66.2 (11.5) years. The majority of 
patients were opioid-tolerant (n = 55; 65.5%); patients were 
previously treated with oxycodone (n = 27; 32.1%), tramadol 
(n = 20; 23.8%), fentanyl (n = 6; 7.1%), or morphine (n = 2; 
2.4%). Among the opioid-tolerant patients, only four patients 
received more than 120 mg/day of morphine equivalent 
dose of opioid prior to switching to tapentadol: two patients 
received 100 mg/day of oxycodone and two patients received 
120 mg/day of oxycodone. Approximately 41, 37, and 23% 
of patients were assessed as having mixed pain, neuropathic 
pain, and nociceptive pain, respectively.
Effectiveness
Following tapentadol administration, 92.9% (78 of 84) 
of all patients achieved clinically relevant pain relief 
(i.e., at least 50% reduction in NRS score from baseline) 
within a median (range) of 4 (1–13) days. The propor-
tion of responders in patients with mixed, nociceptive, 
and neuropathic pain were 91.1% (31/34), 100% (19/19), 
and 90.3% (28/31), respectively. The median (range) NRS 
score decreased significantly from 7 (4–10) at baseline to 
2 (0–6) at initial pain relief (P < 0.0001; Fig. 1). At the 
time of initial pain relief, the median (range) daily dose 
of tapentadol was 100 (50–300) mg. During the mainte-
nance period, the increase in median (range) daily dose of 
tapentadol to 200 (100–600) mg resulted in further pain 
relief in 56 of 78 (71.8%) of patients. In these 56 patients, 
the median (range) NRS score decreased from 2 (0–6) at 
initial pain relief to 1 (0–5) at the end of the maintenance 
period (P < 0.0001; Fig. 1).
Table 1  Patient demographics and characteristics (N = 84)
Data are presented as mean (SD), unless otherwise stated
a Opioid-naïve
b Neuropathic and nociceptive pain
All patients (N = 84)




Body mass index 20.9 (3.2)
Height (cm) 159.1 (8.2)
Body weight (kg) 53.3 (10.3)


















Pain type, n (%)
 Mixed  painb 34 (40.5)
 Neuropathic pain 31 (36.9)
 Nociceptive pain 19 (22.6)
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In six of 84 patients, tapentadol was started in median 
(range) daily dose of 75 (50–200) mg and increased to daily 
dose of up to 100–400 mg. In these six patients, the median 
(range) NRS score was 6 and remained unchanged from 
baseline to the end of the maintenance period; they were 
considered non-responders and were subsequently switched 
to other opioid analgesics such as oxycodone or transdermal 
fentanyl.
Effectiveness in opioid‑tolerant patients
Of 55 opioid-tolerant patients, 52 patients (94.5%) achieved 
clinically relevant pain relief within a median of 3 days and 
were responders. The median (range) NRS score decreased 
from 7 (4–10) at baseline to 3 (0–6) at initial pain relief. The 
median (range) NRS scores decreased from 3 (0–6) at initial 
pain relief to 1 (0–5) at the end of the maintenance period.
Effectiveness in opioid‑naïve patients
Of 29 opioid-naïve patients, 26 patients (89.7%) achieved 
clinically relevant pain relief within a median (range) of 3 
(1–11) days and were responders. The median (range) NRS 
scores decreased from 8 (4–10) at baseline to 2 (0–4) at ini-
tial pain relief (P < 0.0001; Fig. 2). At the time of initial pain 
relief, the median (range) daily dose of tapentadol was 100 
(50–200) mg. During the maintenance period, the increase in 
median (range) daily dose of tapentadol to 200 (75–400) mg 
resulted in further pain relief in 19 of 26 (73.1%) patients. In 
these 19 patients, the median (range) NRS scores decreased 
from 2 (0–4) at initial pain relief to 1 (0–2) at the end of the 
maintenance period (P < 0.05).
Safety and tolerability
At baseline, nausea was observed in 22 of 84 (26.2%) 
patients, of whom 19 were opioid-tolerant and three were 
opioid-naïve. Nausea disappeared in nine of 19 (47.3%) 
patients who had exhibited nausea caused by previous strong 
opioids. No opioid-naïve patients experienced nausea or 
vomiting during tapentadol treatment. Only three opioid-
tolerant patients experienced nausea which was assessed to 
be related to tapentadol by the physician. During the main-
tenance period, three patients discontinued tapentadol due to 
general health deterioration caused by disease progression. 
No patients discontinued tapentadol or had dose reduction 
due to serious adverse events, and none exhibited withdrawal 
symptoms. There were no somnolence or delirium which 
required treatment discontinuation or dose reduction.
Discussion
This study aimed to evaluate the effectiveness, safety, and 
tolerability of tapentadol in Japanese patients with moder-
ate-to-severe cancer pain. The findings revealed that tapent-
adol was effective at relieving cancer pain and well tolerated 
in both opioid-tolerant and opioid-naïve patients during the 
study period. More than 90% of patients with neuropathic 
pain or mixed pain, and all patients with nociceptive pain 
were responders.
Previous exposure to opioids, among others such as pain 
type (i.e., neuropathic pain), and progressive disease, can 
influence a patient’s response to analgesic treatment [14, 
26] and, hence, efficacy outcomes. In the present study, we 
observed a significant reduction in pain intensity scores from 
Fig. 1  Median numerical rating score (NRS) pain intensity scores 
over time in the overall study population. Boxes indicate 25th (bot-
tom) and 75th (top) percentiles; horizontal line within boxes indicates 
median; error bars indicate 10th–90th percentiles. ****P < 0.0001
Fig. 2  Median numerical rating score (NRS) pain intensity scores 
over time in opioid-naïve patients. Boxes indicate 25th (bottom) and 
75th (top) percentiles; horizontal line within boxes indicates median; 
error bars indicate 10th–90th percentiles. ****P < 0.0001; *P < 0.05
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baseline through to the maintenance period in both opioid-
naïve and opioid-tolerant patients. These findings suggest 
that tapentadol was effective at alleviating moderate-to-
severe cancer pain regardless of previous exposure to opi-
oids and corroborate those from Kress and colleagues [21], 
who reported that tapentadol was non-inferior to morphine 
in managing moderate-to-severe cancer pain in both opi-
oid-naïve and opioid-tolerant patients. Although our study 
did not have an active comparator to compare the effective-
ness for pain relief, it is notable that pain was significantly 
relieved in patients who switched to equivalent dose of 
tapentadol.
Both ascending and descending pathways are implicated 
in pain and are common sites of actions of analgesics [17, 
27]. Tapentadol has a dual mechanism of action as a mu-
opioid receptor agonist of the ascending pathway and as a 
noradrenaline reuptake inhibitor of the descending path-
way [17, 18]. Noradrenaline plays an important role in pain 
modulation, particularly that of neuropathic pain [18, 28]. 
In rat models of spinal nerve ligation, tapentadol administra-
tion induced a stronger noradrenergic inhibition over mu-
receptor agonism [29]. Furthermore, both α2-adrenoceptor 
agonism and mu-receptor agonism were almost completely 
reversed by selective antagonists, atipamezole and naloxone, 
respectively, highlighting the exclusive synergy between 
both noradrenaline reuptake inhibition and mu-opioid recep-
tor agonism [29].
In the present study, 41, 37, and 23% of patients were 
assessed as having mixed pain, neuropathic pain, and noci-
ceptive pain, respectively. All patients with nociceptive pain 
and more than 90% of patients with neuropathic pain or 
mixed pain were responders. These findings highlight tapen-
tadol’s effectiveness not only for cancer-related nociceptive 
pain, but also neuropathic pain and the results are mirrored 
in other studies [21, 24, 30–32].
Tapentadol’s additional mechanism of action (i.e., inhibi-
tion of noradrenaline reuptake via α2-adrenoceptors) [28] 
means that it is able to alleviate both nociceptive pain and 
neuropathic pain [17–19]. This unique characteristic distin-
guishes tapentadol from most other strong/WHO step III 
opioids (i.e., morphine and fentanyl) that are mainly mu-
opioid receptor agonists [33]. Indeed, tapentadol has dem-
onstrated effectiveness and tolerability in Japanese patients 
with cancer-related neuropathic pain that was unresponsive 
to previous opioid therapy [24]. Other studies supporting 
tapentadol for cancer-related neuropathic pain have been 
mainly conducted in European patients [21, 30]. Tapentadol 
has also shown to be a suitable option for chemotherapy-
induced neuropathic pain [31]. By targeting both nociceptive 
and neuropathic pain, tapentadol could improve treatment 
adherence and outcomes (e.g., quality of life), and minimize 
the potential for adverse effects [34].
Gastrointestinal side effects are commonly associated 
with opioid therapy [35]. In the present study, we evaluated 
the incidence of nausea and vomiting before and after tap-
entadol treatment and observed a favorable gastrointestinal 
tolerability, especially in opioid-naïve patients. Notably, no 
opioid-naïve patients experienced nausea or vomiting during 
tapentadol treatment and only three opioid-exposed toler-
ant patients experienced nausea which was considered to be 
related to the treatment. No patients discontinued tapentadol 
during treatment. We acknowledge that we are unable to 
draw conclusive statements regarding tapentadol’s safety as 
opioid-induced adverse effects extend beyond nausea and 
vomiting. Nevertheless, published literature have demon-
strated the acceptable safety and tolerability profile of tap-
entadol in patients with cancer-related pain [21, 24, 30–32]. 
Besides, tapentadol has also demonstrated better gastroin-
testinal tolerability due to its dual mechanism of action and 
weaker affinity for the mu-opioid receptor compared to other 
full mu-opioid receptor agonists [19, 22].
This study also presents some inherent limitations. For 
example, the retrospective study design limited our scope 
of analysis and interpretations as pertinent information (e.g., 
duration of previous opioid therapy, stable or progressive 
disease, etc.) were lacking due to the use of data originally 
recorded for other purposes. Additionally, having an active 
comparator would have provided a more balanced represen-
tation of tapentadol’s clinical effectiveness. Our study would 
also benefit from evaluating the reduction in pain intensity 
across subgroups of patients with different pain types. Fur-
thermore, this was a single-center study where the size of 
the study population was small and all patients were treated 
at the same center; the results should, therefore, be inter-
preted with caution. However, it is notable that our results 
are consistent with those of other studies. Although these 
limitations are important, our study adds on to the evidence 
of the real-world use of tapentadol in Japanese patients with 
cancer pain, and provides valuable insights into the use of 
tapentadol in a different ethnic patient population compared 
with those from previously conducted studies.
In conclusion, our study showed that tapentadol is effec-
tive and well tolerated in opioid-naïve and opioid-tolerant 
Japanese patients with cancer pain of varying pathophysiol-
ogy, including those with a nociceptive and/or neuropathic 
components. Tapentadol is a valuable option for opioid-
naïve or opioid-tolerant patients with inadequate pain relief 
or intolerable adverse effects with other opioids.
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